Q-omics provides the consensus-scored TRIM14 profile across patient tissues and cancer cell-line models. TRIM14 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRIM14 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TRIM14 RNA expression shows 18,510 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where TRIM14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM14 survival associations across molecular data types. TRIM14 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM14 RNA expression–survival associations across cancer types. High TRIM14 expression shows unfavorable associations in UCEC, LGG and HNSC, but favorable associations in SKCM, KIRC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRIM14 RNA expression.
This table summarizes TRIM14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM14 shows higher tumor expression in KIRC, THCA, STAD, BRCA, HNSC and BLCA. The KIRC box plot shows higher TRIM14 RNA expression in tumor versus normal tissue (log2 FC = +1.703, t-test p < 0.001).
This table shows molecular features associated with TRIM14 in patient tissues and cancer cell lines. In patient samples, TRIM14 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
